Immuno-Oncology
Chronic Immune-Related Adverse Events Are Common in Certain Melanoma Subgroups
April 17, 2021
Article
Chronic immune-related adverse effects arising from adjuvant anti–PD-1 therapy in patients with high-risk melanoma are more common than previously recognized, and often persisted with longer follow-up.
Immunotherapy Enters Gastroesophageal and Gastric Cancers
March 25, 2021
Article
Namrata (Neena) Vijayvergia, MD, discusses the emerging role of immunotherapy in resectable and metastatic esophageal and gastric cancers, as well as key nuances that could complicate these agents’ utility in clinical practice.
Checkpoint Inhibitors in Lung Cancer: The Progress Continues
March 19, 2021
Article
Edgardo Santos, MD, FACP, discusses advances made with immunotherapy regimens in the first-line treatment of patients with metastatic non–small cell lung cancer and areas of active investigation.
FDA to Reassess Accelerated Immunotherapy Approvals
March 12, 2021
Article
Six indications for immune checkpoint inhibitors granted under the FDA’s accelerated approval process that later failed confirmatory clinical trials are being reassessed as the agency continues an industry-wide evaluation of the pathway.
Immunotherapy Only Gets Better in NSCLC
February 23, 2021
Article
Immunotherapy continues to improve upon the treatment of non-small cell lung cancer, and there are more exciting advancements on the horizon.
Pembrolizumab-Ipilimumab Combo Boosts Toxicity, Not Survival in NSCLC
February 07, 2021
Article
Pembrolizumab (Keytruda) combined with ipilimumab (Yervoy) did not improve survival and had higher rates of toxicity compared with pembrolizumab monotherapy as a first-line treatment for patients with metastatic non–small cell lung cancer (NSCLC) who had a PD-L1 tumor proportion score (TPS) of 50% or greater, and did not harbor EGFR or ALK aberrations.
Immunotherapy May Highlight Neoadjuvant Treatment's Use in Lung Cancer
January 25, 2021
Article
The radiographic and pathologic responses that have been seen with checkpoint inhibitors in lung cancer bodes well for the use of neoadjuvant therapy. However, the relationship between response and long-term outcomes, specifically with regard to overall survival, will have to be teased out before they become standard practice, explained David Spigel, MD.
FDA Approves Cabozantinib Plus Nivolumab for Frontline Advanced RCC
January 23, 2021
Article
The FDA approved cabozantinib (Cabometyx) plus nivolumab (Opdivo) for the frontline treatment of patients with advanced renal cell carcinoma (RCC).
Early Study Lays Groundwork for Boosting Immunotherapy Response
December 29, 2020
Article
Regulating the fas protein may be the key in overcoming resistance in patients receiving immunotherapy treatment, such as CAR T-cell therapy.
Immunotherapy for Small Cell Lung Cancer: Expert Provides Updates
November 09, 2020
Article
Chemoimmunotherapy regimens are showing promise in the treatment of SCLC.